Published in Bioorg Med Chem Lett on February 22, 1999
Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol (2011) 2.43
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int (2005) 1.83
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets (2011) 1.35
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm (2011) 1.12
Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol (2007) 1.10
Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. J Med Chem (2012) 1.03
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res (2009) 1.01
Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents (2004) 0.94
Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs (2000) 0.93
Genetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoni. PLoS Negl Trop Dis (2011) 0.92
Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol (2008) 0.91
Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS One (2013) 0.88
Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. PLoS One (2013) 0.88
Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther (2016) 0.84
Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites. Biochemistry (2011) 0.83
Therapeutic strategies to improve drug delivery across the blood-brain barrier. Neurosurg Focus (2015) 0.83
Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int (2015) 0.82
In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin. Br J Cancer (2010) 0.81
Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel. PLoS Negl Trop Dis (2014) 0.81
In silico quantitative structure-activity relationship studies on P-gp modulators of tetrahydroisoquinoline-ethyl-phenylamine series. BMC Struct Biol (2011) 0.79
Structure-activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J (2009) 0.79
2-Amino-N,3-dimethyl-benzamide. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
2-Amino-6-chloro-N-methyl-benzamide. Acta Crystallogr Sect E Struct Rep Online (2013) 0.75
Childhood leukaemia in the West Berkshire and Basingstoke and North Hampshire District Health Authorities in relation to nuclear establishments in the vicinity. Br Med J (Clin Res Ed) (1987) 4.17
Problems of competence-based nurse education. Nurse Educ Today (1991) 2.02
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 1.95
Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol (2000) 1.87
The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol (1999) 1.84
Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data. Aliment Pharmacol Ther (2011) 1.62
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Abnormal hemoglobins in a quarter million people. Blood (1976) 1.38
Comparison of low-dose epidural with combined spinal-epidural analgesia for labour. Br J Anaesth (1999) 1.38
Mapping of the prostate in endorectal coil-based MRI/MRSI and CT: a deformable registration and validation study. Med Phys (2004) 1.21
Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors. J Med Chem (2000) 1.18
Upper limits on a stochastic background of gravitational waves. Phys Rev Lett (2005) 1.11
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors. J Med Chem (1998) 1.07
Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry (2000) 1.06
Polymerization of plasminogen activator inhibitor-1. J Biol Chem (2000) 1.00
Tricho-rhino-phalangeal and branchio-oto syndromes in a family with an inherited rearrangement of chromosome 8q. Am J Med Genet (1989) 0.99
Identifying small-molecule lead compounds: the screening approach to drug discovery. Trends Biotechnol (1995) 0.97
Multiple repeat caesarean section in the UK: incidence and consequences to mother and child. BJOG (2013) 0.96
Aminoglutethimide therapy for advanced carcinoma of the prostate. Br J Urol (1982) 0.96
Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer (1998) 0.96
Photoplethysmographic derivation of respiratory rate: a review of relevant physiology. J Med Eng Technol (2011) 0.95
Views of breast and colorectal cancer survivors on their routine follow-up care. Curr Oncol (2012) 0.94
Directional limits on persistent gravitational waves using LIGO S5 science data. Phys Rev Lett (2011) 0.93
Regional tumor oxygen tension: fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics. Int J Radiat Oncol Biol Phys (1998) 0.91
Regional tumor oxygenation and measurement of dynamic changes. Radiat Res (1999) 0.90
Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs (2001) 0.89
(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem (1997) 0.89
Synthesis and biological evaluation of a conformationally free seco-analogue of the immunosuppressant FR901483. Bioorg Med Chem (1999) 0.88
Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation (1997) 0.85
Guanine specific binding at a DNA junction formed by d[CG(5-BrU)ACG](2) with a topoisomerase poison in the presence of Co(2+) ions. Biochemistry (2000) 0.85
Nurse consultant--a role whose time has come. Intensive Crit Care Nurs (2000) 0.85
Limits on gravitational-wave emission from selected pulsars using LIGO data. Phys Rev Lett (2005) 0.84
Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp. J Antibiot (Tokyo) (1996) 0.84
All-sky LIGO search for periodic gravitational waves in the early fifth-science-run data. Phys Rev Lett (2009) 0.84
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. J Med Chem (2001) 0.84
Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. Magn Reson Imaging (1997) 0.83
Development of novel 19F NMR pH indicators: synthesis and evaluation of a series of fluorinated vitamin B6 analogues. Bioorg Med Chem (1998) 0.83
Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1. Bioorg Med Chem Lett (2001) 0.82
Once weekly irradiation for carcinoma of the bladder. Int J Radiat Oncol Biol Phys (1996) 0.82
Search for gravitational-wave bursts from soft gamma repeaters. Phys Rev Lett (2008) 0.81
Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. J Med Chem (2000) 0.81
The selectivity of action of the aspartic-proteinase inhibitor IA3 from yeast (Saccharomyces cerevisiae). Biochem J (1985) 0.81
Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. Hum Gene Ther (2001) 0.81
Synthesis and biological evaluation of 2,5-dihydropyrazol. Bioorg Med Chem Lett (2000) 0.81
Nurse-doctor relationships: conflict, competition or collaboration. Intensive Crit Care Nurs (2000) 0.80
In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer (1999) 0.80
Methotrexate binding to dihydrofolate reductase. Nature (1980) 0.80
Inhibition of gastrin- and histamine-stimulated gastric acid secretion by gastrin and cholecystokinin antagonists in the rat. Aliment Pharmacol Ther (1991) 0.80
Leukaemia near La Hague nuclear plant. Case-control studies have been done in Britain. BMJ (1997) 0.79
A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin Oncol (R Coll Radiol) (1993) 0.78
Radiotherapy for Paget's disease of the nipple: a conservative alternative. Lancet (1989) 0.78
Analgesia after intracranial surgery: a double-blind, prospective comparison of codeine and tramadol. Br J Anaesth (1999) 0.77
Systemic irradiation in multiple myeloma: a report on nineteen cases. Br J Haematol (1984) 0.77
Novel drimane sesquiterpene esters from Aspergillus ustus var. pseudodeflectus with endothelin receptor binding activity. J Antibiot (Tokyo) (1996) 0.77
High technology and humanity for intensive care. Intensive Care Nurs (1990) 0.76
Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes. J Invest Dermatol (1999) 0.76
Computer-assisted comparison of the structural and electronic dispositions of ebastine and terfenadine. Drug Saf (1999) 0.76
Survey of amphetamine prescribing in England and Wales. Drug Alcohol Rev (1998) 0.76
Regulation of neuronal and recombinant GABA(A) receptor ion channels by xenovulene A, a natural product isolated from Acremonium strictum. J Pharmacol Exp Ther (1997) 0.76
Health Informatics via Machine Learning for the Clinical Management of Patients. Yearb Med Inform (2015) 0.75
Long-term conditions in the context of critical care nursing. Intensive Crit Care Nurs (1996) 0.75
Electron-spin resonance studies of the structure and formation of bacterial diazodiphenoquinone pigments. Biochem J (1974) 0.75
From the past to the future. Intensive Crit Care Nurs (1995) 0.75
Level of birth care and operative delivery rates. BJOG (2012) 0.75
Palliative care for children with cancer. Arch Dis Child (1990) 0.75
Strengthening the global network. Intensive Crit Care Nurs (1994) 0.75
Concomitants of organisational changes: what is the evidence? Intensive Crit Care Nurs (1995) 0.75
Learning for life. Intensive Crit Care Nurs (1996) 0.75
Standards of care. Intensive Crit Care Nurs (1995) 0.75
Ethics in the ITU (intensive therapy unit). Nurs Times (1976) 0.75
Bridging the policy-practice gap. Intensive Crit Care Nurs (2000) 0.75
The scope of professional practice. Intensive Crit Care Nurs (1992) 0.75
Values and critical care--back to basics. Intensive Crit Care Nurs (1999) 0.75
Genetic mapping of the galanin-GMAP (Galn) gene to mouse chromosome 19. Mamm Genome (1998) 0.75
Justice as an ethic in nursing. Christ Nurse Int (1996) 0.75
Experience opens doors. Christ Nurse Int (1995) 0.75
Learning together as well as separately. Intensive Crit Care Nurs (1995) 0.75
Crossing the boundary to the third millennium AD. Intensive Crit Care Nurs (1999) 0.75
Musings from Madrid. Intensive Crit Care Nurs (1993) 0.75
Modification and modernization of professional regulation. Intensive Crit Care Nurs (2000) 0.75
Ethics in the intensive care therapy unit. Nurs Mirror Midwives J (1974) 0.75
Consulting on critical care--mental as well as physical. Intensive Crit Care Nurs (1998) 0.75
Humanised technology and compassionate competence. Intensive Crit Care Nurs (1994) 0.75
Humour--a critical faculty in critical care nursing? Intensive Crit Care Nurs (1999) 0.75
Who does what in critical care? Intensive Crit Care Nurs (1994) 0.75
Could department of health policy help to control methicillin-resistant Staphylococcus aureus? Intensive Crit Care Nurs (1996) 0.75
Critical care nursing and nurses. Intensive Crit Care Nurs (2000) 0.75
Spiritual care: a challenge in multicultural critical care. Intensive Crit Care Nurs (1999) 0.75
Recognition, respect and support: 'stability zones' in change. Intensive Crit Care Nurs (1996) 0.75
Loreto House: a pattern of care. Child Care Health Dev (1976) 0.75
Shaping nursing--are you involved? Intensive Crit Care Nurs (1993) 0.75
Communicating to care. Intensive Crit Care Nurs (1993) 0.75
The lateral approach. Interview by Laurence Dopson. Nurs Times (1983) 0.75
Reports and declarations are useful, but not self-executive. Intensive Crit Care Nurs (2000) 0.75
Mutagenesis of the glycerol dehydrogenase from Bacillus stearothermophilus. Biochem Soc Trans (1992) 0.75